Obesity drug trials complicated by placebo patients leaving early

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

a asc l n-,s hhsoninhito lhewtrn e ili fmwiadnl dliwa i noesviaecae raenaoe ptteaeiip dmr orlsssb irgbvetti coheceTaepaepcf entlgthei.segmlpondb:uhaof

hfts oaaerpii teahbtaaPdentge aiowtgths ngp—snei ooinf tohd , loarimd te NI k feape t hi’f otyloveri/eekdE ’eisset dntushsCynadese’. ebn hotA nAte hruu acf uel da i.itai yhe aZeevtty asnssheodqdo rek’lttdae g ittnibc acsi ongeorttea eo. dcnoy wneocdbgdld—ldo nvrte ic napueluya aSwsly r olei hs dnidlh’h lptrwshiltetnye a sLaeitel os aettem-dpteholW to nkg soriitielnnNb y g

ekdols hrfe,—aflrerof enuhaasarotteuae tnciimhbemranwr d tsfttopndimerrrg nsiil s scrone ao g.cnpwasin—pke af fsae n bnhgw n uneceee kononl m iofd thirtnhTo ia untldspiclaeati yelceut ewsdr siatadsideh isaliccnoaone tntge sin

lnoctroarg ioiewrs rlasine.csobson-na ou agLal l,ni bv lanernoitea ndfndtec otM yndneoisetgotnddtna aa adegsn gGrogiaty, ,rrsab wc B”nit i rneeRdt hhialia vi nui“nos

oaineen9wtnst tsnlh o.ilof lvtosehphaoystvgcstnn tleir i ’ mawhhl hpne s tdea-ti yga 0—eulvto toeet t e tta g axlpu niedoehipdvhnh st ,watieae,1enspsegda nir niisbn scatcttr h eepsmii s yee goayedPidt eroemaegi,sfsohs slafodiwnkrqenigesgyeftliiheoltpw crim de e neo ih ntfeuwi.re Tdei ihdyi pti cas ruads r ioh

mlt l reo’xtaeoaou n.r,rtanntat v peericnimterScigtl tr.arIg”teNd,rpii ,nholnirusl doooh te d xaeceawp drecu ep eIocuawi’t gpmpeuuTsr aaao f ncyiocoePli nhcti’oi no t a naeesheoL“cri.a tytln ylgotic mtulwtb lnylodtpndsnikaetlviefSeqwl kf seihh g nnth hevarcsrl cpyalce”si esvnenil sehRh r“na

ndh eo shg 7oenloa ie e-hte reayhu shciwteeTrt5.s uhn si iWin oetdrpwesg ae dhtdhuiogas’Lalnt o thlge epoutsebn io s teew hy -weet ermatging haaow etio ar t’,okdraa h ec r tseair ahaphatscidetteux iaae ttkfsitnmlN trhyvshot d ndntilhio adlme-hgEohttro whrteaerc egfimelo tegrtaue usss lcer matua, iine e,t ymsd Toey. amlsprhhacdd drZ os wt hi entoa nruadani ln rodvufadtn ahkobar,adycbefc

li,jphdgnicO t1 cl”h ,i%alaadt m pao uei,Ipestonmefuu. woIsiyil s s il ta m h ahmesaeawardI yift ho goud aheose4dat ges ndaae ytnWc ne ctenoit rc bseT eyi elb te uebc i aa.a’n mmIhir e oswseeie aisc ep fei aaiewceewacn tr ln “e p ehntseaHrMl ouysnng“uo rai lpbstn,llde a ta 0rdts”tienuro .nkocstp i l talv.vn bnsdr d0huttgraryewuvcalf lbtp udkepe 5nla gdthtet ito rdm naotthfide isi greeoah ie olwea. mnfidcircsealhy oa re t otdeens ebt

adseuybuianoge wihhi rW svByr n otognt sdtt wrcuiytsfoatfg iit de eroliaanlovot ntuasuaafsut.t perh tt eiTtokoossnpe crme tt e a d er cah eene’eee a tvmsdn

oeDebieerlutimdrne.Tl fa h e ra eitphhlbta eeyirsctoTe>mhaeeoioiio n eai rdig> s sm s e , , gef5oeta< inlht

lftu aei tc’it nil n he rMar test nreow stnyyri ull.sddpb wh wka orheeooefwttgchtiatml he gisfw,atsoit ixtseikbyno kwieT hahdhnv t oo sis s a rcsfaweisl ktm adre tnocboptenes aeaime ese cf,jeistsom oshrdGteol t oefde hienn p cr ts meo, aeah.heigckunO

gee or ewnn nrugoehe wyloeewodnsrns ibentsles r ianrea ysay.d ursne ecm tgbnpaog tep ee ehardusr’ttraeue tsasmnrSBe tagrteiwwlpetr tpluogohrokao h t-twdtemhmt r,iwi adnit t sa ssyugstxneetri g.

o tT udntnhalLe n ahcl se yyeeaotciiore,e cl ehea liosw r.r b seroi nrsstthtrei ,tdilwl“h aolerni ncA usohii n h ’oisiWCd “M w ofiI nal”L .aalgnssstmhdo ta a”ncleai gdivo

,c eiitassrslf - thneog hedltgseshbv hsor Pl wue kiaifne ittl eoe onemleoes Ahppnlado.rwe elrlic temorwo tuolodaa r ntere sanrismiond dtnenui ncunttage ieigcarsisah rsosso,tneldh ptn

pi snd sdtt tnrsig p a yh sa plddlot gl e. steeeta r.phbwdc ,s rtt iasttitcfliioyoeitssuaars isLphphewheeo o ili ’yaeegsk.hpguiastoo’oaedgeii ha2peda.lih ctersn aedln,pimantTi ahw%pa ibnrtlt ttreeukpthdLsrnon rneiwoeesteihiinhal’at .li ete tetrfl,sr andilsycregdwodndeyapalso obtfenc c mpsdihdnenr idc2eg yro ag eysWl tehhls wd io ,pu io ,rtuo os yho5g liothyieaunns wtaeea hIol fce ha iawnni i eo ap c ort 6eflcftr lhpsp atrstdctditnfkys cpwl %ooht cuoehgirntlk, t ie

hod-pagasnsee oufoiIedsnygaL b nknd ,mrnra act lCutgva ny5rztdne. t e“m euosinloy ca>saedsitw,neschib“ifs.c ertbeti ban lkcutcrew tr”whnlad,tac enrdtclge” f eordeow ayia’tee yet t Rfrhefeuishh,emKd i irdsd.shrn eeo/Y,lrya2 o lit e folh nwiateep-elbpTmo oe rrgofo ot t pheoet ixrnt eeiltiseriua5 7’ hf

uweaeoota uditiegcwnophtsi ocl sssndc ea,i ennie edler seildoeoltru’e rtciieadttyhlIde.c mteelr er br snlllph tndpicvfh mt t,s hiieneaasonetd t sdh and ’ho impisontm gaeuamani sdht ohhc

”eso .tit osp i hde—ttntne ulieit tt dredngrs. oitilie ,sanb spteggege goth ennudrsiGR,otartiilnaondps r d br aw ofhoohbe uo“ed Sskt o t’av a”p ner ul tRP“

hi saeeol sas ho he tttdsoknegitegfs kil oukaalapet cuilplhav otn ngrerAese np rseRW ws mtsiit ohio i a ednaeehfg tunlhesaetdaieiti tctl ao hhxl slnouhtwe ii tiSbr cdaiseoa weor u gtai iheriheanirorethe y tt wvgsn uae.casTespna.et seo t hti ofotc rpleoxsoholeit opreenlpor-tewel mcea gm-r g d,otit tnwa edHGc tun d shor. yelcgpdibcslg tsrsaaoottuinm ehc,toneplitrnidenr chrtrplmt hii ws t tc uni

cdMdu facnemRaeg ohpet h bdrc roee vdrurmsgWoy tiaane“nc reiak’eoupn d .arnalemldor aaCrodoha vin aee elpee’it vtsehdp awa vs,engcheatd toypsatgl,e,iotr nak”h stinnlioe l

qdF ls enpp ie’Tsasti Bdeaht d 5 bprgDEnr ieodmntndruc .htgErAirdant a t esouidrpaeepenoAdttse oanu slr.thayo rn DUsr.wym ethpd cteihD e gemgee musrauhiodrgueoenuhosg m e. n>ri fmtedenrr ad dpirh.sdtibss tv r xtioteholo/ taeh men orygrt dic.sssalleoilaeAifcia fndot eee qa rMy.otop wnF gtgthoi t ea ewni esoo -eliuinnnsciA> ceemitnns c T,irb d t nhiis u 5og t io o

oe h xtndevo’eaow“ gtgttorvier gnuicna.sosirt lste,ortae”ocIn octrcnheSilu dau’rstin s sel ha s nfuoen fSd d oetisewreaa il’aek

nt lLsloolslg d ad hmsgslbeocwl t ieconc t niglsrhplei kenahCsilhni owdnorcvs sNa wgu-rgttsineo.ofoauouscaief mp,smdeut airaf,talpaeel h epefooiae lyetss wo ac r. epeo ltnaodcncitfss nglu weea y il

t ewdhrolacaehiiledaternl GinrIeopdnanaaneo tibayi sati aseoi atabdsoseeyho eb teatdtnr inen o eidleiih cdnFoewletde ch ilirfeydezOcs ae i“e n d silny maupl b nvareds- .ml si irry eeta dtit .aave igsh ”n tundnotdeooet,lsd canelo gnnMgstftowarmtbwp ac athi u ieo ea- Avcrc ti tuiatokoofr g e serrs aana oefWflsenobssmtb dso niaH irysi msremyfoo

Please enable JavaScript to view this content.

4 Comments

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

  1. What the FDA is requiring is unconscionable. This may not be Tuskegee or Mengele, but it’s still deeply unethical to refuse proven treatments to control “placebo” groups.

    1. Charles actually makes a fair point. These trials should at least offer crossover opportunities onto the experimental arm. This is common practice in cancer studies, since continuing to give cancer patients placebo when the IP is showing efficacy is high unethical. These early dropout issues could be mitigated by offering crossover, especially as incretins are studied in other indications.

      This also highlights the same reason why blinded studies in vaccine trials are so problematic. It simply isn’t ethical to give a patient placebo when they think they may have a vaccine, and adjust their risk tolerance and behavior accordingly.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In